Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xanomeline/Trospium (XT) on Cognitive Impairment in Schizophrenia
NCT07084831Phase 3Withdrawn
- Sponsor
- European Group for Research in Schizophrenia
- Start
- Jan 2027
- Primary completion
- Jan 2029
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 10
01
Overview
A Phase 3 trial of xanomeline + trospium chloride in schizophrenia, sponsored by European Group for Research in Schizophrenia. Planned start Jan 2027; status: withdrawn.
02
Drugs
xanomeline + trospium chloride
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07084831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07084831.